Drug Trial Radar · NCT06641089
Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis and Anti-TNFα Inadequate Response
Last checked: Nov 19, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
600
Planned (sponsor's estimate)
Start
Oct 15, 2024
Primary completion
Jan 4, 2027
Study completion Sep 13, 2027
Sponsor
- Lead sponsor
- MoonLake Immunotherapeutics AGIndustry
- Sponsor type
- Industry
- First posted
- Oct 15, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a study to confirm the clinical efficacy and safety of sonelokimab compared with placebo in the treatment of adults with active psoriatic arthritis who have had a previous inadequate response or intolerance to anti-tumor necrosis factor (TNF)α therapy.
Conditions
- Arthritis, Psoriatic
Interventions
SonelokimabDrug
Sonelokimab
PlaceboDrug
Placebo
RisankizumabDrug
Active comparator
Primary outcomes
What the sponsor says the trial is designed to measure.
- Response rate of participants achieving at least a 50% improvement in the American College of Rheumatology criteria (ACR50)Time frame: Week 16 compared to placebo
Locations
143 sites in 11 countries. Site status is shown where the registry gives one.
Clinical Site
Avondale, Arizona
Clinical Site
Chandler, Arizona
Clinical Site
Flagstaff, Arizona
Clinical Site
Mesa, Arizona
Clinical Site
Phoenix, Arizona
Clinical Site
Scottsdale, Arizona
Clinical Site
Tucson, Arizona
Clinical Site
Jonesboro, Arkansas
Clinical Site
La Jolla, California
Clinical Site
Pomona, California
Clinical Site
San Diego, California
Clinical Site
Santa Monica, California
Clinical Site
Thousand Oaks, California
Clinical Site
Upland, California
Clinical Site
Avon Park, Florida
Clinical Site
Clearwater, Florida
Clinical Site
Hialeah, Florida
Clinical Site
Miami Gardens, Florida
Clinical Site
Tampa, Florida
Clinical Site
Zephyrhills, Florida
Clinical Site
Gainesville, Georgia
Clinical Site
Springfield, Illinois
Clinical Site
Lake Charles, Louisiana
Clinical Site
Baltimore, Maryland
Clinical Site
Grand Blanc, Michigan
Clinical Site
Brooklyn, New York
Clinical Site
Rochester, New York
Clinical Site
Charlotte, North Carolina
Clinical Site
Leland, North Carolina
Clinical Site
Middleburg Heights, Ohio
Clinical Site
Portland, Oregon
Clinical Site
Duncansville, Pennsylvania
Clinical Site
Jackson, Tennessee
Clinical Site
Memphis, Tennessee
Clinical Site
Murfreesboro, Tennessee
Clinical Site
Allen, Texas
Clinical Site
Austin, Texas
Clinical Site
Baytown, Texas
Clinical Site
Colleyville, Texas
Clinical Site
Houston, Texas
Showing 40 of 143 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.